---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124514"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:15:30.498619+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports Q3 net loss $84.3M; cash $1.2B; pipeline on track for 2025 pivotal data

## Summary
- Net loss $84.3M for Q3 2024; R&D expenses $60.6M, G&A $15.8M.
- Cash, cash equivalents and marketable securities $1.2B, expected to fund operations into 2028.
- Zidesamtinib (ROS1+) Phase 1 data at ESMO; Phase 2 enrollment ongoing (227 patients), pivotal data expected 2025.
- NVL-655 (ALK+) Phase 2 enrollment ongoing (229 patients); ALKAZAR Phase 3 trial to start H1 2025.
- Appointed Dr. Alice Shaw to Scientific Advisory Board; upsized public offering raised $575M.

## SEC filing metadata
- accession: 0000950170-24-124514
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017024124514/0000950170-24-124514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017024124514/nuvl-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124514
- JSON: https://secwatch.observer/filing/0000950170-24-124514.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.